Progressive Keratoconus Clinical Trial
Official title:
Evaluation of Corneal Hysteresis and Corneal Resistance Factor After Corneal Cross-linking for Keratoconus
This study attempts to compare Corneal Hysteresis (CH) and Corneal Resistance Factor (CRF)
in a series of keratoconic eyes before and after Corneal collagen cross-linking (CXL).
Furthermore, among the objectives of the study is to reveal correlations between CH and CRF
and a series of corneal indexes like the Corneal Thickness (CT), mean keratometry (Km) and
corneal astigmatism (Astig).
The study adhered to the tenets of the Declaration of Helsinki and written informed consent
was given by all participants. The study was conducted at the Eye Institute of Thrace (ΕΙΤ),
in Alexandroupolis, Greece. EΙΤ is a Democritus University research institute focusing
primarily on the conditions of the anterior segment of the eye.
Participants were recruited from the Outpatients Cornea service of the EIT in a consecutive
if eligible basis. Fifty (50) eyes of thirty (30) patients with keratoconus were recruited
for the sake of the study and formed the keratoconus group (KG). Eligible subjects for the
keratoconus group had to present progressive keratoconus in consecutive corneal
topographies, changes in refractive power, and deterioration of the visual acuity within a
period of two years. Exclusion criteria included glaucoma, glaucoma suspicion, and
intraocular pressure (IOP) lowering drugs administration. Further to glaucoma, exclusion
criteria included central corneal thickness (CCT) less than 400μm, K-readings more than 60D,
a history of herpetic keratitis, corneal scarring, severe eye dryness, pregnancy or nursing,
current corneal infection, or underlying autoimmune disease.
Fifty (50) eyes of fifty (50) non-keratoconic, age-matched, individuals who visited our
outpatient service formed the control group (CG). Further to keratoconus, and a spherical
equivalent error above 3D, the same exclusion criteria applied to the control group members,
as well. All participants wearing contact lenses were instructed to discontinue contact lens
wear at least a month before measurements.
CRF and CH parameters were obtained while the patient was sitting on a chair in front of the
Ocular Response Analyzer (ORA; Reichert Ophthalmic Instruments, Buffalo, NY, USA) device.
Upon successful fixation of the patient's eye on a red blinking target, the operator
activated the device. An air puff was released by a non-contact probe, which scanned the
central area of the eye and sent a signal to the ORA. In brief, the air puff causes the
cornea to move inward, past applanation, and into slight concavity. After milliseconds, the
air pumps shut off, the pressure decreases, and the cornea begins to return in its normal
state. The system monitors the entire process and measures two pressure values, which are
determined from the inward and outward applanation processes. The aforementioned measuring
procedure enables the determination of CH which is related to the viscoelastic structure of
the corneal tissue, and is calculated as the difference between the two pressure values at
the two applanation processes, and CRF which is indicative of the overall resistance of the
cornea and is calculated as a linear function of the two pressures associated with the two
applanation. In order to ensure accurate results, ORA was done four times for each eye, by
the same operator. Signals that differ significantly in appearance from the other signals
from the same eye were deleted.
The same surgical procedure was applied to all keratoconus patients that included:
Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application
of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent
de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture
of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2
drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated
and aqueous was stained yellow. The ultraviolet A (UVA) radiation source that was used is
UV-XTM (IROC AG, Zurich, Switzerland). In details, an 8.0mm diameter of central cornea was
irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of
3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during
irradiation, as well, in order to sustain the necessary concentration of the riboflavin.
Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
After treatment all patients were prescribed topical ofloxacin drops qid, fluorometholone
qid and diclofenac nitrate qid, accompanied by frequent instillation of artificial tears.
Soft therapeutic lens was applied until complete re-epithelialization of the cornea was
detected. Follow up visits were performed on the 1st day, 7th day, 1st, 3rd, 6th and 12th
month after the operation.
n/a
Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02721628 -
Epi-keratoplasty Versus Collagen Cross-Linking in Progressive Keratoconus
|
N/A | |
Completed |
NCT02883868 -
Stromal Demarcation Line: is it Predictive for Cross-Linking Efficiency?
|
N/A | |
Active, not recruiting |
NCT04427956 -
Corneal Crosslinking Treatment Study
|
Phase 4 | |
Terminated |
NCT01868620 -
Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.
|
N/A | |
Recruiting |
NCT05314738 -
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06450470 -
Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus
|
Phase 3 | |
Completed |
NCT02117999 -
Transepithelial Corneal Cross-linking Using Iontophoresis
|
N/A | |
Completed |
NCT01485211 -
Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin
|
Phase 4 | |
Completed |
NCT04504578 -
Efficacy and Safety ofCACXL in the Treatment of Keratoconus With Thin Corneas
|
N/A | |
Completed |
NCT00567671 -
Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia
|
Phase 2/Phase 3 | |
Completed |
NCT00647699 -
Corneal Collagen Cross-linking for Progressive Keratoconus
|
Phase 3 | |
Recruiting |
NCT00815256 -
Safety and Effectiveness of Collagen Cross Linking in Progressive Mild and Moderate Keratoconus
|
Phase 3 | |
Recruiting |
NCT04045626 -
Study of Demarcation Line Depth in Transepithelial Versus Epithelium-off Accelerated Cross-linking (AXL) in Keratocouns
|
N/A | |
Completed |
NCT03442751 -
Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
|
Phase 3 | |
Withdrawn |
NCT00679666 -
Corneal Crosslinking in Keratoconus and Corneal Ectasia
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT00925327 -
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus
|
Phase 2 |